Afterwards, CRC cells were analyzed for the fold change in surface marker expression (CD44, CD133, ESA for stemness; MHC I, CD274 for immunomodulation) upon treatment, with each marker’s median fluorescence intensity measured individually by flow cytometry. The gene discussed is CD44; the disease is colorectal carcinoma.